Top

Drugs & Aging

Published in:

01-12-2008 | Therapy In Practice

Herpes Zoster and Postherpetic Neuralgia

Optimizing Management in the Elderly Patient

Authors: Dr Robert W. Johnson, Gunnar Wasner, Patricia Saddier, Ralf Baron

Published in: Drugs & Aging | Issue 12/2008

Abstract

Herpes zoster (HZ) results from reactivation of varicella-zoster virus (VZV) that has been persistent and clinically dormant in spinal ganglia or cranial sensory nerves since primary infection with VZV. The most common reason for reactivation is a decline in zoster-specific cell mediated immunity as a result of aging (immunosenescence). More than two-thirds of HZ cases occur in people ≥60 years of age. HZ incidence is higher in persons who are immunocompromised as a result of disease (e.g. malignancies such as lymphoma, HIV/AIDS, diabetes mellitus) or treatments such as chemotherapy and radiotherapy. HZ incidence is also increased by therapeutic immune suppression following organ transplantation and in patients taking high-dose corticosteroids. However, HZ may occur in otherwise healthy young people. Although serious and life-threatening complications sometimes occur, the most common complication is postherpetic neuralgia (PHN), which may persist for months or years and is significantly resistant to treatment despite substantial advances in the understanding of its pathological mechanisms. The medical and social costs of HZ and PHN are high, particularly in older patients. Prevention of PHN in patients with HZ is unsatisfactory although antiviral drugs reduce the duration of pain after HZ. A live attenuated vaccine has been shown to reduce the incidence of HZ and PHN as well as the burden of illness in subjects aged ≥60 years. In view of the increasing numbers of elderly persons in the population and the poor outcomes of PHN treatment, vaccination against HZ at approximately 60 years of age appears to be an appropriate strategy.

de Melker H, Berbers G, Hahné S, et al. The epidemiology of varicella and herpes zoster in The Netherlands: implications for varicella zoster virus vaccination. Vaccine 2006; 24(18): 3946–52.PubMedCrossRef

Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 2003; 70Suppl. 1: S111–8.PubMedCrossRef

Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998; 3(11): 886–90.PubMedCrossRef

Mandal BK, Mukherjee PP, Murphy C, et al. Adult susceptibility to varicella in the tropics is a rural phenomenon due to the lack of previous exposure. J Infect Dis 1998; 178Suppl. 1: S52–4.PubMedCrossRef

Arvin A. Aging, immunity, and the varicella-zoster virus. N Engl J Med 2005; 352: 2266–7PubMedCrossRef

Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352: 2271–84PubMedCrossRef

Scott FT, Leedham-Green ME, Barrett-Muir WY, et al. A study of shingles and the development of postherpetic neuralgia in East London. J Med Virol 2003; 70Suppl. 1: S24–30PubMedCrossRef

Attal N, Fermanian C, Fermanian J, et al. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion? Pain 2008 Mar 4; 138(2): 343–53PubMedCrossRef

Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25: 571–5PubMed

10.

Yawn BP, Saddier P, Wallen PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341–9PubMedCrossRef

11.

Brisson M, Edmunds WJ. Epidemiology of varicella-zoster virus in England and Wales. J Med Virol 2003; 70Suppl. 1: S9–14PubMedCrossRef

12.

Heymann AD, Chodick G, Karpati T, et al. Diabetes as a risk factor for herpes zoster infection: results of a population-based study in Israel. Infection 2008; 36(3): 226–30PubMedCrossRef

13.

Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9–20PubMed

14.

Ragozzino MW, Melton LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310–6

15.

Donahue JG, Choo PW, Manson JE, et al. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605–9PubMedCrossRef

16.

Bowsher D. The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population. Eur J Pain 1999; 3: 335–42PubMedCrossRef

17.

Helgason S, Sigurdsson J, Gudmundsson S. The clinical course of herpes zoster: a prospective study in primary care. Eur J Gen Pract 1996; 2: 12–5CrossRef

18.

Opstelten W, Van Essen GA, Schellevis F, et al. Gender as an independent risk factor for herpes zoster: a population-based prospective study. Ann Epidemiol 2006; 16(9): 692–5PubMedCrossRef

19.

di Luzio Paparatti UD, Arpinelli F, Visona G. Herpes zoster and its complications in Italy: an observational survey. J Infect 1999; 38(2): 116–9.PubMedCrossRef

20.

Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001; 33(1): 62–9.PubMedCrossRef

21.

Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. Epub 2008 May 9

22.

Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002; 44: 211–9PubMedCrossRef

23.

Edmunds WJ, Brisson M, Gay NJ, et al. Varicella vaccination: a double-edged sword? Commun Dis Public Health 2002; 5: 185–6PubMed

24.

Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127(2): 305–14.PubMedCrossRef

25.

Jung BF, Johnson RW, Griffin DRJ, et al. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545–51PubMedCrossRef

26.

Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007; 7: 1581–95PubMedCrossRef

27.

Scott FT, Johnson RW, Leedham-Green M, et al. The burden of herpes zoster: a prospective population based study. Vaccine 2006; 24: 1308–14PubMedCrossRef

28.

MacIntyre CR, Chu CP, Burgess MA. Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 2003; 131: 675–82PubMedCrossRef

29.

Saddier P, Sy L, Nikas A, et al. Herpes zoster hospitalizations in the United States, 1998–2002 [poster]. 44th Annual Meeting of the Infectious Diseases Society of America (IDSA); 2006 Oct 12–15; Toronto (ON)

30.

Gil A, San-Martin M, Carrasco P, et al. Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 2004; 22: 3947–51PubMedCrossRef

31.

Statistics Canada. Number of deaths attributed to zoster in Canada [online]. Available from URL: http://www.statcan.ca:8096/bsolc/english/bsolc?catno=84-208-XIE [Accessed 2005 Feb 9]

32.

Wood MJ, Kay R, Dworkin RH, et al. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials. Clin Infect Dis 1996; 22: 341–7PubMedCrossRef

33.

Wassilew S. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients: a randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005; 19: 47–55PubMedCrossRef

34.

Keam SJ, Chapman TM, Figgitt DP. Brivudin (bromovinyl deoxyuridine). Drugs 2004; 64: 2091–7PubMedCrossRef

35.

Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007; 44Suppl. 1: S1–26PubMedCrossRef

36.

Tyring S, Barbarash RA, Nahlik JE. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123(2): 89–96PubMed

37.

Jackson JL, Gibbons R, Meyer G, et al. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia: a meta-analysis. Arch Intern Med 1997; 157: 909–12PubMedCrossRef

38.

Alper BS, Lewis PR. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? J Fam Pract 2000; 49: 255–64PubMed

39.

Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896–900PubMedCrossRef

40.

Whitley RJ, Weiss H, Gnann J, et al. The efficacy of steroids and acyclovir therapy of herpes zoster in the elderly. Antiviral Res 1996; 20(1): 67–8CrossRef

41.

Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997; 13: 327–31PubMedCrossRef

42.

van Wijck AJ, Opstelten W, Moons KG, et al. The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial. Lancet 2006; 367: 219–24PubMedCrossRef

43.

Higa K, Dan K, Manabe H, et al. Factors influencing the duration of treatment of acute herpetic pain with sympathetic nerve block: importance of severity of herpes zoster assessed by the maximum antibody titers to varicella-zoster virus in otherwise healthy patients. Pain 1988; 32: 147–57PubMedCrossRef

44.

Manabe H, Dan K, Higa K. Continuous epidural infusion of local anesthetics and shorter duration of acute zoster-associated pain. Clin J Pain 1995; 11: 220–8PubMedCrossRef

45.

Wu CL, Marsh A, Dworkin RH. The role of sympathetic nerve blocks in herpes zoster and postherpetic neuralgia. Pain 2000; 87: 121–9PubMedCrossRef

46.

Hempenstall K, Nurmikko TJ, Johnson RW, et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2005; 2: 628–44CrossRef

47.

Dubinsky RM, Rabbani H, El-Chami Z, et al. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004; 63: 959–65PubMedCrossRef

48.

Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005; 118: 289–305PubMedCrossRef

49.

Wu CL, Raja SN. An update on the treatment of postherpetic neuralgia. J Pain 2008; 9: S19–30PubMed

50.

Johnson RW. Herpes zoster pain including shingles and postherpetic neuralgia. In: Rice A, Wilson P, Watson P, et al., editors. Textbook of clinical pain management: chronic pain volume. 2nd ed. London: Hodder Arnold, 2008: 429–39CrossRef

51.

Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002; 59: 1015–21PubMedCrossRef

52.

Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. Neurology 1982; 32: 671–3PubMedCrossRef

53.

Max MB, Schafer SC, Culnane K. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427–32PubMedCrossRef

54.

Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. Pain 1992; 48: 29–36PubMedCrossRef

55.

Watson CP, Vernich L, Chipman M, et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 51: 1166–71PubMedCrossRef

56.

Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000; 16: 188–92PubMedCrossRef

57.

Rowbotham MC, Reisner LA, Davies PS, et al. Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial. J Pain 2005; 6: 741–6PubMedCrossRef

58.

Ray WA, Meredith S, Thapa PB, et al. Cyclic antidepressants and the risk of sudden cardiac death. Clin Pharmacol Ther 2004; 75: 234–41PubMedCrossRef

59.

Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94: 215–24PubMedCrossRef

60.

Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280: 1837–42PubMedCrossRef

61.

Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004; 109: 26–35PubMedCrossRef

62.

Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003; 60: 1274–83PubMedCrossRef

63.

Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005; 115: 254–63PubMedCrossRef

64.

Oaklander AL, Buchbinder BR. Pregabalin-withdrawal encephalopathy and splenial edema: a link to high-altitude illness? Ann Neurol 2005; 58: 309–12PubMedCrossRef

65.

Bowsher D. The management of postherpetic neuralgia. Postgrad Med J 1997; 73: 623–9PubMedCrossRef

66.

Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104: 323–31PubMedCrossRef

67.

Kalso E, Allan L, Dellemijn PL, et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 2003; 7: 381–6PubMedCrossRef

68.

Rowbotham MC, Reisner-Keller LA, Fields HL. Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991; 41: 1024–8PubMedCrossRef

69.

Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50: 1837–41PubMedCrossRef

70.

Recommendations for the appropriate use of opioids in persistent non-cancer pain [online]. Available from URL: http://www.britishpainsociety.org/book_opioid_main.pdf [Accessed 2008 Oct 7]

71.

American Pain Society. Advocacy: the use of opioids for the treatment of chronic pain [online]. Available from URL: www.ampainsoc.org/advocacy/opioids.htm [Accessed 2008 Oct 7]

72.

Bernstein JE, Korman NJ, Bickers DR, et al. Topical capsaicin treatment of chronic postherpetic neuralgia. J Am Acad Dermatol 1989; 21: 265–70PubMedCrossRef

73.

Watson CP, Tyler KL, Bickers DR, et al. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther 1993; 15: 510–26PubMed

74.

Backonja M. High-concentration capsaicin for the treatment of PHN and HIV neuropathy pain [abstract]. Eur J Pain 2007; 11: S40CrossRef

75.

Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrollment study. Pain 1999; 80: 533–8PubMedCrossRef

76.

Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003; 106: 151–8PubMedCrossRef

77.

Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996; 65: 39–44PubMedCrossRef

78.

Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves postherpetic neuralgia. Ann Neurol 1995; 37: 246–53PubMedCrossRef

79.

Kotani N, Kushikata T, Hashimoto H, et al. Intrathecal methylprednisolone for intractable postherpetic neuralgia. N Engl J Med 2000; 343: 1514–9PubMedCrossRef

80.

Nelson KA, Park KM, Robinovitz E, et al. High-dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 1997; 48: 1212–8PubMedCrossRef

81.

Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic pain. Clin J Pain 2000; 16: S101–5PubMedCrossRef

82.

Haythornthwaite JA, Clark MR, Pappagallo M, et al. Pain coping strategies play a role in the persistence of pain in postherpetic neuralgia. Pain 2003; 106: 453–60PubMedCrossRef

83.

Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005; 352: 1324–34PubMedCrossRef

84.

Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95: 434–41PubMedCrossRef

85.

Marin M, Meissner HC, Seward JF. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008; 122(3): e744–51PubMedCrossRef

86.

Reynolds MA, Chaves SS, Harpaz R, et al. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008; 197Suppl. 2: S224–7PubMedCrossRef

87.

Hardy I, Gershon AA, Steinberg SP, et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325: 1545–50PubMedCrossRef

88.

Gershon AA, LaRussa P, Steinberg S, et al. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996; 173: 450–3PubMedCrossRef

89.

Johnson R. Patient awareness of herpes zoster: the Global Herpes Zoster Survey: a preliminary report. Herpes 2006; 13Suppl. 1: 40–1

90.

Hurley LP, Harpaz R, Daley MF, et al. National survey of primary care physicians regarding herpes zoster and the herpes zoster vaccine. J Infect Dis 2008; 197Suppl. 2: S216–23PubMedCrossRef

Title: Herpes Zoster and Postherpetic Neuralgia
Optimizing Management in the Elderly Patient
Authors: Dr Robert W. Johnson
Gunnar Wasner
Patricia Saddier
Ralf Baron
Publication date: 01-12-2008
Publisher: Springer International Publishing
Published in: Drugs & Aging / Issue 12/2008
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.2165/0002512-200825120-00002

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2008

Adherence to Medication in Patients with Dementia

Acknowledgement

Current Issues in Thromboprophylaxis in the Elderly

Sialorrhoea and Drooling in Patients with Parkinson’s Disease

Older Patients’ Perceptions of Medication Importance and Worth

Medication Withdrawal Trials in People Aged 65 Years and Older

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials